Scholars@Duke
Christine Marie Hunt

Christine Marie Hunt

Adjunct Professor in the Department of Medicine
Medicine, Gastroenterology
Box 3913 Med Ctr, Durham, NC 27710
00550 Hosp South, Durham, NC 27710

Selected Publications

Reply.

Journal Article Gastroenterology · December 2023 Full text Link to item Cite

One ALT Is Not Like the Other.

Journal Article Gastroenterology · August 2023 Full text Link to item Cite

Early Outcomes of SARS-CoV-2 Infection in a Multisite Prospective Cohort of Inpatient Veterans.

Journal Article Open Forum Infect Dis · July 2023 BACKGROUND: Over 870 000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have occurred among Veterans Health Administration users, and 24 000 have resulted in death. We examined early outcomes of SARS-CoV-2 infection in hospitalized ... Full text Link to item Cite

Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.

Journal Article Am J Kidney Dis · March 2023 RATIONALE & OBJECTIVE: Tolvaptan is associated with risk of drug-induced liver injury when used to treat autosomal dominant polycystic kidney disease (ADPKD). After this risk was described based on the clinical trials TEMPO 3:4 and TEMPO 4:4, additional da ... Full text Link to item Cite

Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration.

Journal Article Drug Saf · February 2023 INTRODUCTION: Drug-induced liver injury is a significant health issue, yet the exposure-based incidence remains to be characterized. OBJECTIVE: We aimed to assess the frequency, phenotypes, and outcomes of acute liver injury associated with amoxicillin/cla ... Full text Link to item Cite

Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans.

Journal Article J Gen Intern Med · December 2022 BACKGROUND: Many severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) positive patients take commonly prescribed medications with properties which may affect mortality. OBJECTIVE: Assess if common medications postulated to affect clinical outcomes ... Full text Link to item Cite

Hepatitis B Virus-related Care Quality in Patients With Hepatitis B/Human Immunodeficiency Virus Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study.

Journal Article Clin Infect Dis · October 29, 2022 BACKGROUND: Guideline-adherent hepatitis B virus (HBV) care is critical for patients with HBV, particularly patients with HBV-human immunodeficiency virus (HIV) given increased risks of liver-related complications. However, a comprehensive assessment of HB ... Full text Link to item Cite

Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19.

Journal Article Clin Transl Sci · August 2022 Remdesivir is the first US Food and Drug Administration (FDA)-approved drug for the treatment of coronavirus disease 2019 (COVID-19). We conducted a retrospective pharmacogenetic study to examine remdesivir-associated liver enzyme elevation among Million V ... Full text Link to item Cite

APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.

Journal Article JAMA Intern Med · April 1, 2022 IMPORTANCE: Coronavirus disease 2019 (COVID-19) confers significant risk of acute kidney injury (AKI). Patients with COVID-19 with AKI have high mortality rates. OBJECTIVE: Individuals with African ancestry with 2 copies of apolipoprotein L1 (APOL1) varian ... Full text Link to item Cite

Associations Between Gastrointestinal Symptoms and COVID-19 Severity Outcomes Based on a Propensity Score-Weighted Analysis of a Nationwide Cohort.

Journal Article Gastro Hep Adv · 2022 BACKGROUND AND AIMS: Gastrointestinal (GI) symptoms are well-recognized manifestations of coronavirus disease 2019 (COVID-19). Our primary objective was to evaluate the association between GI symptoms and COVID-19 severity. METHODS: In this nationwide coho ... Full text Link to item Cite

COVID-19-Associated Mortality in US Veterans with and without SARS-CoV-2 Infection.

Journal Article Int J Environ Res Public Health · August 11, 2021 BACKGROUND: We performed an observational Veterans Health Administration cohort analysis to assess how risk factors affect 30-day mortality in SARS-CoV-2-infected subjects relative to those uninfected. While the risk factors for coronavirus disease 2019 (C ... Full text Open Access Link to item Cite

In Reply.

Journal Article Arch Pathol Lab Med · February 1, 2021 Full text Link to item Cite

Alanine Aminotransferase Results Differ by Analyzer Manufacturer in a National Integrated Health Setting, 2012-2017.

Conference Arch Pathol Lab Med · June 2020 CONTEXT.—: Disease guidelines specify universal alanine aminotransferase (ALT) thresholds for clinical decision-making, yet the effect of variability among ALT analyzers remains unclear. OBJECTIVE.—: To compare ALT results from different analyzers from 201 ... Full text Link to item Cite

Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?

Journal Article Fed Pract · February 2019 Improvement in NAFLD may lead to improvement of metabolic syndrome, cardiovascular disease, and malignancy and vice versa. ... Link to item Cite

Identifying and Treating Nonalcoholic Fatty Liver Disease.

Journal Article Fed Pract · January 2019 NAFLD improves with 7% or greater weight loss. ... Link to item Cite

Correction to: Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.

Journal Article Dig Dis Sci · October 2018 The original version of the article unfortunately contained errors in Table 3, Risk Factor column headings "Age > 50 (n = 115)," "Age > 50-64 (n = 154)," and "Age > 65 + (n = 60)." ... Full text Open Access Link to item Cite

Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.

Journal Article Dig Dis Sci · September 2018 BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. Severe NAFLD with advanced fibrosis results in substantial morbidity and mortality. Associated with metabolic syndrome, NAFLD is often initially clinica ... Full text Link to item Cite

Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration.

Journal Article Hepatol Commun · September 2018 Hepatitis B virus (HBV) reactivation may occur with high risk immunosuppression, such as anti-cluster of differentiation (CD)20 antibodies (Abs). Appropriate HBV prophylaxis during anti-CD20 Ab therapy averts hepatitis, chemotherapy disruption, and death. ... Full text Open Access Link to item Cite

Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury.

Journal Article Regul Toxicol Pharmacol · April 2018 We examined the effect of gender, age, and drug properties on liver events reporting frequency (RF) to assess patient- and drug-related risks for drug-induced liver injury (DILI). We performed a data-mining analysis of the WHO VigiBase™ to 1) identify drug ... Full text Link to item Cite

Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.

Journal Article Aliment Pharmacol Ther · January 2018 BACKGROUND: With its increasing incidence, nonalcoholic fatty liver disease (NAFLD) is of particular concern in the Veterans Health Administration (VHA). AIMS: To evaluate risk factors for advanced fibrosis in biopsy-proven NAFLD in the VHA, to identify pa ... Full text Link to item Cite

Drug rechallenge following drug-induced liver injury.

Journal Article Hepatology · August 2017 UNLABELLED: Drug-induced hepatocellular injury is identified internationally by alanine aminotransferase (ALT) levels equal to or exceeding 5× the upper limit of normal (ULN) appearing within 3 months of drug initiation, after alternative causes are exclud ... Full text Link to item Cite

Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013.

Journal Article Mil Med · October 2016 We assessed implementation of precision medicine within the Veterans Health Administration. We analyzed the use of interleukin-28B (IL28B) pharmacogenetic test, which predicts interferon-α treatment response in patients with hepatitis C. Patients with favo ... Full text Link to item Cite

Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.

Journal Article Regul Toxicol Pharmacol · June 2016 Few epidemiologic studies describe longitudinal liver chemistry (LC) elevations in cancer patients. A population-based retrospective cohort was identified from 31 Phase 2-3 oncology trials (excluding targeted therapies) conducted from 1985 to 2005 to evalu ... Full text Open Access Link to item Cite

Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.

Journal Article World J Gastroenterol · May 21, 2016 AIM: To evaluate pretreatment hepatitis B virus (HBV) testing, vaccination, and antiviral treatment rates in Veterans Affairs patients receiving anti-CD20 Ab for quality improvement. METHODS: We performed a retrospective cohort study using a national repos ... Full text Open Access Link to item Cite

Children's liver chemistries vary with age and gender and require customized pediatric reference ranges.

Journal Article Regul Toxicol Pharmacol · October 2015 Used to detect liver disease and injury, baseline liver chemistry distributions were evaluated by age and gender in children without known liver disease. Baseline liver chemistries [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline ... Full text Link to item Cite

Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™.

Journal Article Regul Toxicol Pharmacol · August 2015 Polypharmacy is common, and may modify mechanisms of drug-induced liver injury. We examined the effect of these drug-drug interactions on liver safety reports of four drugs highly associated with hepatotoxicity. In the WHO VigiBase™, liver event reports we ... Full text Link to item Cite

Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database.

Journal Article Regul Toxicol Pharmacol · November 2014 BACKGROUND/AIMS: Age-differences in the frequency and manifestations of drug-induced liver injury are not fully characterized. Data-mining analyses were performed to assess the impact of age on liver event reporting frequency with different phenotypes and ... Full text Link to item Cite

An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data.

Journal Article Pharmacoepidemiol Drug Saf · June 2014 PURPOSE: The aim of this study was to develop an automated causality assessment algorithm to identify drug-induced liver injury. METHODS: The Roussel Uclaf Causality Assessment Method (RUCAM) is an algorithm for determining the causal association between a ... Full text Link to item Cite

A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.

Journal Article Pharmacoepidemiol Drug Saf · June 2013 PURPOSE: Identifying drug-induced liver injury is a critical task in drug development and postapproval real-world care. Severe liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT) >3× upper limit of normal (ULN) and ... Full text Link to item Cite

Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.

Journal Article Pharmacogenomics · April 2013 Tyrosine kinase inhibitors (TKIs) represent important therapeutic alternatives to, or combinations with, traditional cytotoxic chemotherapy. Despite their selective molecular targeting and demonstrated clinical benefit, TKIs produce a range of serious adve ... Full text Link to item Cite

Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data.

Journal Article Pharmacoepidemiol Drug Saf · February 2013 PURPOSE: To evaluate the incidence, phenotypes, and outcomes of drug-associated liver injury identified in electronic medical record (EMR) data using standardized criteria for drug-induced liver injury (DILI). METHODS: This retrospective cohort study used ... Full text Link to item Cite

Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.

Journal Article Drug Saf · October 1, 2012 BACKGROUND: Potential severe liver injury is identified in clinical trials by ALT >3 × upper limits of normal (ULN) and total bilirubin >2 × ULN, and termed 'Hy's Law' by the US FDA. However, there is limited evidence or validation of these thresholds in c ... Full text Link to item Cite

A pre-marketing ALT signal predicts post-marketing liver safety.

Journal Article Regul Toxicol Pharmacol · August 2012 Drug induced liver injury during drug development is evidenced by a higher incidence of serum alanine aminotransferase (ALT) elevations in treated versus placebo populations and termed an "ALT signal". We sought to quantify whether an ALT signal in pre-mar ... Full text Link to item Cite

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.

Journal Article Clin Pharmacol Ther · April 2012 Lapatinib is a clinically important component of the treatment for HER2-positive metastatic breast cancer and has an acceptable safety profile. Lapatinib-associated Hy's Law cases have been characterized using human leukocyte antigen (HLA) DQA1*02:01/DRB1* ... Full text Link to item Cite

Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease.

Journal Article Regul Toxicol Pharmacol · March 2012 BACKGROUND: The FDA provides guidance regarding pre-marketing liver chemistry subject stopping criteria. This study was undertaken to determine the background rates of liver chemistry abnormalities in pediatric clinical trials for conditions with and witho ... Full text Link to item Cite

Case definition and phenotype standardization in drug-induced liver injury.

Journal Article Clin Pharmacol Ther · June 2011 Drug-induced liver injury (DILI) is the most frequent reason cited for the withdrawal of approved drugs from the market and accounts for up to 15% of the cases of acute liver failure. Investigators around the globe have begun to identify and study patients ... Full text Link to item Cite

The evaluation of drug rechallenge: the casopitant Phase III program.

Journal Article Regul Toxicol Pharmacol · December 2010 Drug rechallenge (or reinitiation), following an event of drug-induced liver injury, is associated with 13% mortality in prospective series. Rechallenge generally results in much more rapid injury than the initial liver event. The neurokinin-1 antagonist c ... Full text Link to item Cite

Background incidence of serum creatinine threshold rises in a predominantly female clinical trial population without underlying renal disease

Journal Article Regulatory Toxicology and Pharmacology · November 1, 2010 Objective: Serum creatinine (Cr) is used to monitor renal function during pre-marketing clinical trials. Standard thresholds for a serum creatinine (Cr) increase predictive of renal injury remain to be established in this setting. Study design and setting: ... Full text Cite

Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.

Journal Article Drug Saf · June 1, 2010 BACKGROUND: Challenges exist in the clinical diagnosis of drug-induced liver injury (DILI) and in obtaining information on hepatotoxicity in humans. OBJECTIVE: (i) To develop a unified list that combines drugs incriminated in well vetted or adjudicated DIL ... Full text Link to item Cite

Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.

Journal Article Clin Gastroenterol Hepatol · August 2009 BACKGROUND & AIMS: Acetaminophen-induced liver injury is the most common cause of acute liver failure in the United States; it occurs inadvertently in approximately half of all cases. Concomitant use of other medications might impact susceptibility to acet ... Full text Link to item Cite

Drug-induced liver injury following positive drug rechallenge.

Journal Article Regul Toxicol Pharmacol · June 2009 Drug rechallenge (or reinitiation), following an event of drug-induced liver injury, can lead to serious or fatal liver injury. A retrospective review of a large pharmaceutical safety database was conducted to assess clinical outcomes of positive drug rech ... Full text Link to item Cite

Evidence-based liver chemistry monitoring in drug development

Journal Article Pharmaceutical Medicine · January 1, 2009 Background: Liver safety issues affect patients and may result in compound termination during drug development or drug withdrawal postmarketing. While liver chemistries are monitored to protect patient safety, the frequency and timing of monitoring is larg ... Full text Cite

Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1.

Conference Pharmacogenomics · January 2009 The 4th Drug Information Association Workshop in a series of workshops on Pharmacogenomics: 'Biomarkers and Pharmacogenomics in Drug Development and Regulatory Decision Making' took place on December 10-12, 2007 in Bethesda, MD, USA. A number of breakout s ... Full text Link to item Cite

Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease.

Journal Article Regul Toxicol Pharmacol · November 2008 BACKGROUND: The FDA has recently proposed pre-marketing liver chemistry subject stopping criteria. The study was undertaken to determine the background rates of liver chemistry abnormalities in clinical trial populations without underlying liver disease. M ... Full text Link to item Cite

Monitoring liver safety in drug development: the GSK experience.

Journal Article Regul Toxicol Pharmacol · November 2007 To promptly identify and evaluate liver safety events, an evidence-based liver safety system was created for global Phase I-III clinical trials. The goals of this system included improving clinical trial subject safety, expanding information on liver safet ... Full text Link to item Cite

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

Journal Article Clin Infect Dis · March 15, 2003 YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined ... Full text Link to item Cite

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.

Journal Article Am J Gastroenterol · March 2001 OBJECTIVES: Alosetron (Lotronex) is a new therapeutic agent for irritable bowel syndrome (IBS) in women with diarrhea-predominant IBS. This multicenter randomized, double-blind, placebo-controlled study assessed the safety and tolerability of alosetron dur ... Full text Link to item Cite

Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.

Journal Article Hepatology · July 2000 Hepatic iron concentration has consistently been observed as being directly correlated with the response to interferon therapy in chronic hepatitis C virus (HCV). We therefore conducted a randomized, controlled trial comparing iron reduction by phlebotomy ... Full text Link to item Cite

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria.

Journal Article Am J Gastroenterol · May 1999 OBJECTIVE: Irritable bowel syndrome (IBS) is diagnosed by the presence of a constellation of symptoms fulfilling the Manning or Rome Criteria, after exclusion of organic disease. To exclude other diagnoses that might contribute to the abdominal pain or bow ... Full text Link to item Cite

Evaluation of a workplace hemochromatosis screening program.

Journal Article Am J Prev Med · May 1999 Hemochromatosis is a common inherited disorder of iron metabolism with significant health consequences for the employed population. Although screening for hemochromatosis has been recommended, workplace screening programs remain uncommon. In the first year ... Full text Link to item Cite

Liver disease in pregnancy.

Journal Article Am Fam Physician · February 15, 1999 Acute viral hepatitis is the most common cause of jaundice in pregnancy. The course of acute hepatitis is unaffected by pregnancy, except in patients with hepatitis E and disseminated herpes simplex infections, in which maternal and fetal mortality rates a ... Link to item Cite

Alterations in colonic mucosal vessels in patients with cirrhosis and noncirrhotic portal hypertension.

Journal Article Hum Pathol · May 1998 Changes in intestinal mucosal microvasculature as a cause of lower gastrointestinal hemorrhage in patients with portal hypertension have been well documented clinically, but the analogous histomorphological changes have not been well characterized. The goa ... Full text Link to item Cite

Effect of postoperative complications on health and employment following liver transplantation.

Journal Article Clin Transplant · April 1998 The influence of postoperative complications on employment and health status following orthotopic liver transplantation (OLT) remains elusive. Postoperative complications were scored prospectively using a standardized medical outcome classification in each ... Link to item Cite

Effect of postoperative complications on health and employment following liver transplantation

Journal Article Clinical Transplantation · April 1, 1998 The influence of postoperative complications on employment and health status following orthotopic liver transplantation (OLT) remains elusive. Postoperative complications were scored prospectively using a standardized medical outcome classification in each ... Cite

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.

Journal Article Dig Dis Sci · December 1997 Studies of interferon-alpha (IFN-alpha) therapy for chronic hepatitis C have focused on viral clearance; however, few have evaluated patient's health-related quality of life during therapy. This study evaluates health-related quality of life and the preval ... Full text Link to item Cite

Medical problems occurring after orthotopic liver transplantation.

Journal Article Dig Dis Sci · August 1997 Liver transplantation is complicated by specific medical problems. Diabetes mellitus occurs in 4-20% of patients undergoing liver transplantation. Patients with primary sclerosing cholangitis and ulcerative colitis experience up to a 13% incidence of colon ... Full text Link to item Cite

Hepatitis C and Cancer

Journal Article Annals of Internal Medicine · June 15, 1997 Full text Cite

Hepatitis C in pregnancy.

Journal Article Obstet Gynecol · May 1997 OBJECTIVE: To review the epidemiology and clinical course of hepatitis C virus (HCV) infection, to examine current data on the vertical transmission of HCV to neonates, and to develop recommendations for intrapartum and postpartum follow-up of neonates bor ... Full text Link to item Cite

Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient.

Journal Article Liver Transpl Surg · March 1997 A 42-year-old white man with morbid obesity and hypertriglyceridemia was noted to have nonalcoholic steatohepatitis (NASH) at the time of a laparoscopic cholecystectomy for presumed gallstone pancreatitis. His postoperative course was complicated by a 50-k ... Full text Link to item Cite

Alterations in colonic mucosal vessels in patients with portal hypertension.

Journal Article LABORATORY INVESTIGATION · January 1, 1997 Link to item Cite

Hepatitis C.

Journal Article Ann Intern Med · October 15, 1996 OBJECTIVES: To review the virology, epidemiology, pathogenesis, natural history, clinical manifestations, and current treatment of hepatitis C virus (HCV) infection. DATA SOURCES: The MEDLINE database (1966 to 1996) was searched for English-language articl ... Full text Link to item Cite

Effect of orthotopic liver transplantation on employment and health status.

Journal Article Liver Transpl Surg · March 1996 Employment, functional status, health status, and prevalence of anxiety and depression were assessed in patients who had undergone orthotopic liver transplantation at Duke University from 1984 to 1993 to identify social and economic factors that might infl ... Full text Link to item Cite

Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis.

Journal Article Dig Dis Sci · March 1996 A variety of cholestatic liver diseases appear to primarily affect the biliary epithelium, including cystic fibrosis (CF). CF results from a defect in the chloride channel protein, cystic fibrosis transmembrane conductance regulator (CFTR). Although the ma ... Full text Link to item Cite

Therapy for spontaneous umbilical hernia rupture.

Journal Article Am J Gastroenterol · February 1995 Link to item Cite

Tetracycline-induced bile duct paucity and prolonged cholestasis.

Journal Article Gastroenterology · December 1994 Acute self-limited liver disease has been associated with tetracycline use. However, severe prolonged cholestatic hepatitis and bile duct paucity have not been previously attributed to tetracyclines. Hepatitis, characterized by prolonged jaundice, severe p ... Full text Link to item Cite

Effects of inhibition and induction of cytochrome P-450 isozymes on hyperoxic lung injury in rats.

Journal Article Am J Respir Cell Mol Biol · August 1992 Pulmonary oxygen toxicity most likely results from excessive production of reactive oxygen species. The role of the cytochromes P-450 in this process is controversial because these enzymes have been reported both to enhance hyperoxic lung injury and to pro ... Full text Link to item Cite

Effect of age and gender on the activity of human hepatic CYP3A.

Journal Article Biochem Pharmacol · July 22, 1992 Many pharmacokinetic investigations in the elderly population reveal decreased clearance of lipophilic drugs metabolized by the cytochrome P450 enzymes; however, few studies have evaluated aging-dependent or gender-related changes in specific cytochrome P4 ... Full text Link to item Cite

Hepatic cytochrome P-4503A (CYP3A) activity in the elderly.

Journal Article Mech Ageing Dev · June 1992 Elderly patients exhibit decreased clearance of multiple drugs biotransformed by the hepatic cytochromes P-450. The cytochromes P-450 are a superfamily of enzymes, which comprise a central component of phase I drug metabolism. Distinct isoforms metabolize ... Full text Link to item Cite

Characterization of human liver cytochromes P-450 involved in theophylline metabolism.

Journal Article Drug Metab Dispos · 1992 Theophylline is metabolized in the liver by one or more cytochrome P-450 enzymes. To assess the amounts and types of these human cytochromes P-450, we incubated theophylline with microsomes prepared from 22 different human livers in the presence of NADPH, ... Link to item Cite

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol.

Journal Article Clin Pharmacol Ther · January 1992 The N-demethylation of erythromycin and 6 beta-hydroxylation of cortisol are both functions of the glucocorticoid-inducible CYP3A in human liver microsomes. To determine whether 6 beta-hydroxylation and erythromycin N-demethylation are catalyzed by similar ... Full text Link to item Cite

Regulation of rat hepatic cytochrome P450IIE1 in primary monolayer hepatocyte culture.

Journal Article Xenobiotica · December 1991 1. Rat hepatic cytochrome P450IIE1 is an ethanol-inducible enzyme which catalyses ethanol oxidation and activation of the procarcinogen, N-nitrosodimethylamine (NDMA) to its carcinogenic metabolite. 2. Initial studies in adult rat indicated that the regula ... Full text Link to item Cite

HUMAN HEPATIC CYTOCHROME P-450IIIA ACTIVITY IN THE ELDERLY

Journal Article JOURNAL OF THE AMERICAN GERIATRICS SOCIETY · August 1, 1991 Link to item Cite

In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.

Journal Article Antimicrob Agents Chemother · April 1990 Some quinolone antibiotics cause increases in levels of theophylline in plasma that lead to serious adverse effects. We investigated the mechanism of this interaction by developing an in vitro system of human liver microsomes. Theophylline (1,3-dimethylxan ... Full text Link to item Cite